Serologic response to hepatitis B vaccine with high dose and increasing number of injections in HIV infected adult patients

Seroprevalence of HBV and HIV Co-infection in Children in Nnewi, South-East, Nigeria

“…While the prevalence rate of HBV obtained among HIV negative (0.8%) in this study is comparable to findings of an Ibadan [29] study (0.5%) that used similar method of assay it is however, lower than the reports from other studies [30,31]. This may be related to differences in population characteristics such as exposure to risk factors, socioeconomic status, HBV immunization rates and methods of assay.…”

Prevalence and virological profiles of hepatitis B infection in human immunodeficiency virus patients

“…Indeed, the assessment of these patients showed that 6 of them had active viral B infection (HBsAg positive and anti-HBcAb positive), 13 patients had past HBV infection with immunization status (HBsAg negative, anti-HBcAb and anti-HBs Ab positive) and 14 of them had past B virus infection with antiHBs Ab clearance (HBsAg negative, anti-HBcAb positive without anti-HBs Ab). Several studies showed that HBV vaccination efficiency depends on the immunity status of HIV-positive patients [30][31][32][33] . Therefore, there is a good correlation between CD4+ T-cell count and vaccinal response [30][31][32][33] .…”

“…Several studies showed that HBV vaccination efficiency depends on the immunity status of HIV-positive patients [30][31][32][33] . Therefore, there is a good correlation between CD4+ T-cell count and vaccinal response [30][31][32][33] . This aspect has never been studied in our context.…”

Safety and Immunogenicity of 4 Intramuscular Double Doses and 4 Intradermal Low Doses vs Standard Hepatitis B Vaccine Regimen in Adults With HIV-1

“…6,8,9,[12][13][14][15][16][17] Another possible approach to increasing response to HBV antigen is the use of the intradermal route.…”

“…18 Both high hepatitis B vac-cine doses and use of the intradermal route are well tolerated. 6,14,18 However, available data on alternative HBV vaccination schedules remain insufficient to support changes in current guidelines in the HIV setting.…”